ePrints

Clinical and neuropathological differences between Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies – current issues and future directions

Lookup NU author(s): Dr Lauren WalkerORCiD, Professor Johannes Attems

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2019 International Society for Neurochemistry Lewy body diseases share clinical, pathological, genetic and biochemical signatures, and are regarded as a highly heterogeneous group of neurodegenerative disorders. Inclusive of Parkinson's disease (PD), Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB), controversy still exists as to whether they should be considered as separate disease entities or as part of the same disease continuum. Here we discuss emerging knowledge relating to both clinical, and neuropathological differences and consider current biomarker strategies as we try to improve our diagnostic capabilities and design of disease modifying therapeutics for this group of debilitating neurodegenerative disorders. (Figure presented.).

Publication metadata

Author(s): Walker L, Stefanis L, Attems J

Publication type: Review

Publication status: Published

Journal: Journal of Neurochemistry

Year: 2019

Volume: 150

Issue: 5

Pages: 467-474

Print publication date: 23/08/2019

Online publication date: 20/03/2019

Acceptance date: 14/03/2019

ISSN (print): 0022-3042

ISSN (electronic): 1471-4159

Publisher: Blackwell Publishing Ltd

URL: https://doi.org/10.1111/jnc.14698

DOI: 10.1111/jnc.14698

PubMed id: 30892688

Share